Cyntellect Expands Existing Partnership in Japan to Include Distribution of Celigo™ Adherent Cell Cytometer
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, announces the availability of the Celigo™ Adherent Cell Cytometer in Japan.
According to the Company, Celigo is the non-invasive in situ live cell imaging platform providing speed, flexibility and precision of cellular analysis across a wide range of applications. The announcement follows Cyntellect’s recent distribution deals covering China, Taiwan, South Korea, Singapore, Malaysia and Thailand.
“SPI has built a solid reputation through significant experience with the sale and support of sophisticated capital equipment, knowledge of the cell biology space and established sales, support and service infrastructure. Cyntellect customers will be well served by SPI in this expanded relationship.”
Celigo will be distributed by Cyntellect’s long-standing partner in Japan, Summit Pharmaceuticals International Corporation (SPI).
In addition to Celigo, SPI also distributes Cyntellect’s LEAP Workstation for laser-enabled analysis and processing in Japan. Cyntellect products are sold and supported directly in North America and Europe through the Company’s own team of sales, scientific and service staff.
“The benefits of the Celigo Cell Cytometer can bridge gaps in the emerging Japanese biotech industry,” said Saiid Zarrabian, Cyntellect’s President and Chief Executive Officer. “The speed and precision provided by the Celigo allows for more communication between the world of academia and industry. We see a tremendous sales opportunity as the Japanese bio sector advances.”
Added Mr. Zarrabian, “SPI has built a solid reputation through significant experience with the sale and support of sophisticated capital equipment, knowledge of the cell biology space and established sales, support and service infrastructure. Cyntellect customers will be well served by SPI in this expanded relationship.”
According to the Company, Celigo is the non-invasive in situ live cell imaging platform providing speed, flexibility and precision of cellular analysis across a wide range of applications. The announcement follows Cyntellect’s recent distribution deals covering China, Taiwan, South Korea, Singapore, Malaysia and Thailand.
“SPI has built a solid reputation through significant experience with the sale and support of sophisticated capital equipment, knowledge of the cell biology space and established sales, support and service infrastructure. Cyntellect customers will be well served by SPI in this expanded relationship.”
Celigo will be distributed by Cyntellect’s long-standing partner in Japan, Summit Pharmaceuticals International Corporation (SPI).
In addition to Celigo, SPI also distributes Cyntellect’s LEAP Workstation for laser-enabled analysis and processing in Japan. Cyntellect products are sold and supported directly in North America and Europe through the Company’s own team of sales, scientific and service staff.
“The benefits of the Celigo Cell Cytometer can bridge gaps in the emerging Japanese biotech industry,” said Saiid Zarrabian, Cyntellect’s President and Chief Executive Officer. “The speed and precision provided by the Celigo allows for more communication between the world of academia and industry. We see a tremendous sales opportunity as the Japanese bio sector advances.”
Added Mr. Zarrabian, “SPI has built a solid reputation through significant experience with the sale and support of sophisticated capital equipment, knowledge of the cell biology space and established sales, support and service infrastructure. Cyntellect customers will be well served by SPI in this expanded relationship.”
